Financial Review: Kyndryl (NYSE:KD) versus Axe Compute (NASDAQ:AGPU)

Axe Compute (NASDAQ:AGPU) and Kyndryl (NYSE:KD) are both technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Risk and Volatility

Axe Compute has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500. Comparatively, Kyndryl has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

Institutional and Insider Ownership

9.0% of Axe Compute shares are owned by institutional investors. Comparatively, 71.5% of Kyndryl shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by company insiders. Comparatively, 2.0% of Kyndryl shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Axe Compute and Kyndryl’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axe Compute	-7,769.61%	-1,606.56%	-355.39%
Kyndryl	0.58%	12.24%	1.33%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Axe Compute and Kyndryl, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1	0	0	0	1.00
Kyndryl	2	7	0	0	1.78

Kyndryl has a consensus price target of $16.50, suggesting a potential upside of 36.91%. Given Kyndryl’s stronger consensus rating and higher probable upside, analysts plainly believe Kyndryl is more favorable than Axe Compute.

Earnings & Valuation

This table compares Axe Compute and Kyndryl”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120,000.00	1,171.56	-$233.10 million	($5.75)	-2.11
Kyndryl	$15.09 billion	0.17	$199.00 million	$0.37	32.57

Kyndryl has higher revenue and earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than Kyndryl, indicating that it is currently the more affordable of the two stocks.

Summary

Kyndryl beats Axe Compute on 11 of the 13 factors compared between the two stocks.

About Axe Compute

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

About Kyndryl

Kyndryl Holdings, Inc. operates as a technology services company and IT infrastructure services provider worldwide. The company offers cloud services; core enterprise and zCloud services; application, data, and artificial intelligence services; digital workplace services; security and resiliency services; and network services and edge services. It serves financial, communications, retail and travel, and automotive industries. The company was incorporated in 2020 and is headquartered in New York, New York.